HitGen Inc. A (688222.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE1000040G3
HitGen Inc. A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 426.99 m CNY | 525.57 m CNY |
| Gross profit | 221.44 m CNY | 284.98 m CNY |
| Operating income | 86.56 m CNY | 132.74 m CNY |
| EBIT | 75.80 m CNY | 132.18 m CNY |
| Net income | 51.36 m CNY | 109.51 m CNY |
| Diluted EPS – continuing operations | 0.13 CNY | 0.27 CNY |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About HitGen Inc. A
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company's product pipeline also includes HG146, which is in phase Ia clinical trial is a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation. In addition, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Further, the company focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. The company was incorporated in 2012 and is based in Chengdu, China.
More stocks
- AddLife AB (ALIF B.ST)
- Dno ASA (DNO.OL)
- CA Immobilien Anlagen AG (CAI.VI)
- Fulltech Fiber Glass (1815.TWO)
- Elmos Semiconductor (ELG.DE)
- BBVA Banco Frances SA ADR (BBAR)
- Hangzhou Robam Appliances Co Ltd (002508.SZ)
- ENTERPRISE FINANCIAL SERVICES CORP (EFSC)
- Jiangsu Shemar Electric Co Ltd (603530.SS)
- Micronics Japan Co Ltd (6871.T)
- Hunan Aerospace Huanyu Communication Technology Co. Ltd. A (688523.SS)
- Gossamer Bio, Inc. (GOSS)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.